Journal article · 2024 · Open access

Higher infection risk for JAK inhibitors tofacitinib and baricitinib compared to subcutaneous biological DMARDs

M. Opdam, N. Den Broeder, Bart J. F. van den Bemt, Kelly Mulder, Kayleigh M van de Wiel, Hanne van Ballegooijen, Reinout van Crevel, Alfons A den Broeder

Clinical Rheumatology, 43(6), 2133–2138 · Published 4 May 2024 · DOI 10.1007/s10067-024-06980-x

Open PDFView at the publisherCite this paper

In brief

“Higher infection risk for JAK inhibitors tofacitinib and baricitinib compared to subcutaneous biological DMARDs” is a 2024 journal article by M. Opdam and 7 co-authors, published in Clinical Rheumatology. OpenAlex counts 18 citations as of 19 November 2026. It is open access: the full text is free to read at Radboud Repository (Radboud University).

Citations
18
Most cited in
2025 (9)
Field-weighted impact
4.08
References
17
Authors
8

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Opdam, M., Den Broeder, N., van den Bemt, B. J. F., Mulder, K., van de Wiel, K. M., van Ballegooijen, H., van Crevel, R., & den Broeder, A. A. (2024). Higher infection risk for JAK inhibitors tofacitinib and baricitinib compared to subcutaneous biological DMARDs. Clinical Rheumatology, 43(6), 2133–2138. https://doi.org/10.1007/s10067-024-06980-x

MLA 9

Opdam, M., et al. “Higher infection risk for JAK inhibitors tofacitinib and baricitinib compared to subcutaneous biological DMARDs.” Clinical Rheumatology, vol. 43, no. 6, 2024, pp. 2133–2138. https://doi.org/10.1007/s10067-024-06980-x.

Chicago

Opdam, M., N. Den Broeder, Bart J. F. van den Bemt, Kelly Mulder, Kayleigh M van de Wiel, Hanne van Ballegooijen, Reinout van Crevel, and Alfons A den Broeder. 2024. “Higher infection risk for JAK inhibitors tofacitinib and baricitinib compared to subcutaneous biological DMARDs.” Clinical Rheumatology 43 (6): 2133–2138. https://doi.org/10.1007/s10067-024-06980-x.

Harvard

Opdam, M. et al. (2024) ‘Higher infection risk for JAK inhibitors tofacitinib and baricitinib compared to subcutaneous biological DMARDs’, Clinical Rheumatology, 43(6), pp. 2133–2138. doi:10.1007/s10067-024-06980-x.

IEEE

M. Opdam et al., “Higher infection risk for JAK inhibitors tofacitinib and baricitinib compared to subcutaneous biological DMARDs,” Clinical Rheumatology, vol. 43, no. 6, pp. 2133–2138, 2024, doi: 10.1007/s10067-024-06980-x.

BibTeX

@article{opdam2024higher,
  title     = {{Higher infection risk for JAK inhibitors tofacitinib and baricitinib compared to subcutaneous biological DMARDs}},
  author    = {Opdam, M. and Den Broeder, N. and van den Bemt, Bart J. F. and Mulder, Kelly and van de Wiel, Kayleigh M and van Ballegooijen, Hanne and van Crevel, Reinout and den Broeder, Alfons A},
  journal   = {Clinical Rheumatology},
  year      = {2024},
  volume    = {43},
  number    = {6},
  pages     = {2133--2138},
  doi       = {10.1007/s10067-024-06980-x},
  url       = {https://doi.org/10.1007/s10067-024-06980-x}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Citations by year

YearCitationsShare of the best year
202411
202599
202688

Its field-weighted citation impact is 4.08: it has been cited 4.08 times as often as the average work of the same field, type and year (1.00 is the world average).

Topic and keywords

Health Sciences › Medicine › Rheumatology › Rheumatoid Arthritis Research and Therapies

  • rheumatoid arthritis
  • JAK inhibitors
  • tofacitinib
  • baricitinib
  • biologic DMARDs
  • infection risk
  • herpes zoster
  • antibiotic prescribing

Work with this paper

Most-cited papers in Medicine

All highly cited Medicine papers

Questions about this paper

How do I cite this paper in APA style?

Opdam, M., Den Broeder, N., van den Bemt, B. J. F., Mulder, K., van de Wiel, K. M., van Ballegooijen, H., van Crevel, R., & den Broeder, A. A. (2024). Higher infection risk for JAK inhibitors tofacitinib and baricitinib compared to subcutaneous biological DMARDs. Clinical Rheumatology, 43(6), 2133–2138. https://doi.org/10.1007/s10067-024-06980-x

How many times has this paper been cited?

18 times, according to OpenAlex on 19 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at Radboud Repository (Radboud University): sign in and open the PDF from this page.

Who wrote this paper?

M. Opdam, N. Den Broeder, Bart J. F. van den Bemt, Kelly Mulder, Kayleigh M van de Wiel, Hanne van Ballegooijen, Reinout van Crevel, Alfons A den Broeder.

What is the DOI of this paper?

10.1007/s10067-024-06980-x, permanently at https://doi.org/10.1007/s10067-024-06980-x. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 19 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.